Any current/future new fundraising through debt or equity?

No mention of any new fundraising through debt or equity was made during the call. The company is currently net debt-free with a cash reserve of INR266 crores, indicating strong financial health. Capex plans include INR130-200 crores investment over the next 18-24 months, primarily funded through internal accruals and IPO proceeds (INR40 crores allocated to existing facilities). Management indicated focus is on capex investments rather than new fundraising at this time. They are open to future acquisition opportunities but did not specify any fundraising plans for those. Overall, current strat

Any current/future capex/capital investment/strategic investment?

Current capex includes INR130 crores invested in a new Greenfield project over 18-24 months to build a 5.5 lakh sq. ft. plant on 36 acres, focusing on heavy engineering, petrochemicals, and multi-product manufacturing. Additional INR40 crores is planned for existing facilities upgrades. Total upcoming investment is approximately INR170-200 crores. This capex is expected to boost revenue to INR3,000 crores consol basis once complete. Separate shell and tube heat exchanger unit is being established and will start partial production by Q4 FY '26 and full production from April 2027. INR130 crores

Future growth expectations in sales/revenue/volumes?

Expected revenue growth of 20%-25% in FY '26 driven by increased pharma and chemical industry capex. Incremental revenue potential up to INR 3,000 crores following planned capex investments of INR 130-200 crores. Launch and scaling of new products (shell and tube heat exchangers, conductivity glass-lined reactors) to add 30%-40% revenue growth to glass lining division. Heat exchanger production capacity starting at 200 units per month from January 2027, expandable to 600-700 units per month based on demand. Revenue from conductivity glass reactors anticipated post certification, expected to be

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets 20%-25% revenue growth in FY '26, driven by increased pharma capex, chemical sector growth, and new product launches like shell and tube heat exchangers and conductivity glass. Expected EBITDA margins are strong, aiming to maintain between 18%-20%, supported by cost savings and export growth. Expansion includes INR130-200 crore capex in new facilities (Greenfield project with 5.5 lakh sq ft plant), targeting diversification into petrochemicals and heavy engineering. Current EBITDA margin is around 19.1%, with robust operational discipline. PAT margin in FY '25 was 11.0%, gr

Current/ Expected Orderbook/ Pending Orders?

The company has a strong order book for the coming year, with approximately 80% of orders already booked based on fast delivery capabilities. Recent product launches, including shell and tube heat exchangers and conductivity glass-lined reactors, have received robust market response. Within 15 days of launching shell and tube heat exchangers, 150 orders have been received, with deliveries expected over 4 months. The heat exchanger business is fully booked for the next 9 months, indicating strong demand. The Greenfield expansion project (5.5 lakh sq ft plant) is expected to be completed in 18-2

Standard Engineering Technology LtdQ1 FY26

Standard Engineering Technology Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹298P/E: 69.3Market Cap: ₹5.5K Cr

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Expected revenue growth of 20%-25% in FY '26 driven by increased pharma and chemical industry capex.
→Incremental revenue potential up to INR 3,000 crores following planned capex investments of INR 130-200 crores.
→Launch and scaling of new products (shell and tube heat exchangers, conductivity glass-lined reactors) to add 30%-40% revenue growth to glass lining division.
→Heat exchanger production capacity starting at 200 units per month from January 2027, expandable to 600-700 units per month based on demand.
→Revenue from conductivity glass reactors anticipated post certification, expected to be a game changer in the industry.
→Export market expansion with global partners boosting sales outside India and Japan.
→Completion of 5.5 lakh sq.ft. Greenfield plant in 18-24 months targeting heavy engineering and petrochemical sectors, enabling new revenue streams.

Margin guidance

Category 3

→The company targets 20%-25% revenue growth in FY '26, driven by increased pharma capex, chemical sector growth, and new product launches like shell and tube heat exchangers and conductivity glass.
→Expected EBITDA margins are strong, aiming to maintain between 18%-20%, supported by cost savings and export growth.
→Expansion includes INR130-200 crore capex in new facilities (Greenfield project with 5.5 lakh sq ft plant), targeting diversification into petrochemicals and heavy engineering.
→Current EBITDA margin is around 19.1%, with robust operational discipline.
→PAT margin in FY '25 was 11.0%, growing 14.4% year-on-year, with expectations to sustain or improve margins through efficiency and new products.
→Production ramp-up: Shell & tube heat exchangers full production expected from April 2027, contributing 30%-40% revenue growth in glass lining division.
→The company is net debt-free with strong cash reserves of INR266 crores, supporting future growth investments.

3 more insights locked — sign up free to unlock

Fundraise plans

→No mention of any new fundraising through debt or equity was made during the call.
→The company is currently net debt-free with a cash reserve of INR266 crores, indicating strong financial health.
→Capex plans include INR130-200 crores investment over the next 18-24 months, primarily funded through internal accruals and IPO proceeds (INR40 crores allocated to existing facilities).
→Management indicated focus is on capex investments rather than new fundraising at this time.
→They are open to future acquisition opportunities but did not specify any fundraising plans for those.
→Overall, current strategy emphasizes funding growth through operational cash flows and existing cash reserves without raising new debt or equity.

Order book

Yes

→The company has a strong order book for the coming year, with approximately 80% of orders already booked based on fast delivery capabilities.
→Recent product launches, including shell and tube heat exchangers and conductivity glass-lined reactors, have received robust market response.
→Within 15 days of launching shell and tube heat exchangers, 150 orders have been received, with deliveries expected over 4 months.
→The heat exchanger business is fully booked for the next 9 months, indicating strong demand.
→The Greenfield expansion project (5.5 lakh sq ft plant) is expected to be completed in 18-24 months, supporting future order fulfillment.
→Order booking momentum is positive, with anticipated 20%-25% revenue growth in FY '26 backed by increased inquiries and confirmed orders from pharma and chemical sectors.
→Export consignments deferred previously are expected to contribute positively in Q1 FY '26.
→Overall, the order pipeline remains robust with optimistic revenue forecasts.

Capex plans

Yes

→Current capex includes INR130 crores invested in a new Greenfield project over 18-24 months to build a 5.5 lakh sq. ft. plant on 36 acres, focusing on heavy engineering, petrochemicals, and multi-product manufacturing.
→Additional INR40 crores is planned for existing facilities upgrades.
→Total upcoming investment is approximately INR170-200 crores.
→This capex is expected to boost revenue to INR3,000 crores consol basis once complete.
→Separate shell and tube heat exchanger unit is being established and will start partial production by Q4 FY '26 and full production from April 2027.
→INR130 crores capex is anticipated to achieve an 8-9 times asset turnover post-expansion.
→The company has a 20-year global strategic partnership with GL HAKKO Japan and other international partners to enhance market and product reach.
→The focus is on expanding into petrochemicals, heavy engineering, and increasing export participation.

How does Standard Engineering Technology Ltd rank vs peers in ?

Pro feature

1Standard Engineering Technology Ltd

Rev 2Mar 3

See full sector rankings

Want more stocks like Standard Engineering Technology Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio